PriceSensitive

VIVO Cannabis™ (TSX:VIVO) completes first shipment to Beacon Medical Germany GmbH

Cannabis
TSX:VIVO
21 October 2021 14:30 (EDT)

VIVO Cannabis’s (VIVO) subsidiary ABcann Medicinals has completed its first shipment of EU-GMP certified Canadian dried flower medical cannabis into Europe.

This follows ABcann Medicinals receiving EU-GMP certification in March 2021, and VIVO’s wholly-owned German subsidiary Beacon Medical Germany GmbH receiving an import licence from Germany’s Brandenburg health authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit, as well as its first import permit from Germany’s BfArM, the Federal Institute for Drugs and Medical Devices in July 2021.

“This is a monumental milestone for VIVO. We thank our team for their dedication over the last few years to get us to this point,” commented Ray Laflamme, Canna Farms’ Co-Founder and VIVO’s Chief Executive Officer.

“We are excited to kick-off VIVO’s commercial business in Germany, as our second international medical cannabis market after Australia. We are confident that our products will be just as successful with patients in Germany as they have proved to be with patients in Australia,” added Laflamme.

Beacon Medical Germany GmbH will be responsible for commercialization in Germany. “We look forward to introducing premium quality Beacon Medical™ products to physicians, pharmacists and patients in Europe,” commented Andreas Sander, VIVO’s President of European Operations.

Beacon Medical™ product will undergo full range quality testing for market release in a German GMP-certified specialized lab to ensure the highest product quality and patient safety.

VIVO Cannabis™ is recognized for trusted, premium cannabis products and services. It holds production and sales licences from Health Canada and operates world-class indoor and seasonal airhouse cultivation facilities.

VIVO Cannabis’s (VIVO) is trading at C$0.09 at 1:46 pm ET.

Related News